STOCK TITAN

News for REPCF Stock

RepliCel Provides Corporate Update RepliCel Announces Material Patent Milestones in Key Markets DermaPrecise(TM) Injection System Shown to Produce Consistently High Cell Count and Viability for Cell Therapy Injections RepliCel’s Manufacturing Inspected by Japan’s PMDA CORRECTION: Independent Laboratory Test Results Confirm Value of DermaPreciseTM Injection Consistency in Clinical Simulation Testing Independent Laboratory Test Results Confirm Value of DermaPrecise (TM) Injection Consistency in Clinical Simulation Testing RepliCel Announces Material Patent Milestones RepliCel Closed Final Tranche of Strategic Investment Commitment RepliCel Terminates License Agreement with Shiseido RepliCel Ships DermaPrecise(TM) Injector Prototypes and Consumables to Independent Laboratory for Clinical Simulation Testing RepliCel’s Clinical Advisory Team Delivers Skin Rejuvenation Clinical Study Synopsis to its Japanese Regulatory and Clinical Study Management Team RepliCel Announces DermaPrecise Trademark for Dermal Injector Product Line RepliCel Announces Dermal Injector Update RepliCel Files Notice of Arbitration against Shiseido Company to Resolve its License Agreement Dispute Regarding its Androgenetic Alopecia Cell Therapy RepliCel Life Sciences Appoints One of Japan's Foremost Regenerative Medicine Industry Business Leaders as Strategic Advisor RepliCel and University of Victoria Collaboration Leads to Bioengineering Innovations, Funding, and Patents RepliCel Applies for Manufacturing Approval for Its Collagen and Tissue Regeneration Cell Therapies RepliCel Adds Independent Director RepliCel Launches Testing of Dermal Injector Units RepliCel Launches Preparations for Second Skin Rejuvenation and Tendon Regeneration Clinical Studies RepliCel Announces Appointment of Leading Dermatologist in Japan as Clinical Advisor RepliCel Launches the Next Stage of a Research Project with the University of British Columbia to Build World-Class Hair Follicle Cell Data Map RepliCel Announces Record Year in Patents Granted RepliCel Announces Appointment of Leading Sports Medicine Expert as Orthopedics Clinical Advisor (Japan) RepliCel Closes Second Tranche of Strategic Investment Commitment RepliCel Presents Its Technology Development and Commercialization Plans for Japan at Kanagawa Regenerative Medicine Industry Conference RepliCel Closes First Tranche of Strategic Investment Commitment RepliCel CEO Provides Corporate Update
Back to Sitemap